SCRIP
CITELINE COMMERCIAL

26 Jun 2024 | **Analysis**

China Biotech Podcast: [redacted]EHA[redacted]ADA[redacted]

by Brian Yang

In this Chinese-language podcast episode, "Angus" Shipo Xie, a lawyer at Han Kun Law, joins Brian Yang to discuss the implications of China's updated Data Overseas Transfer rules issued in late March. Dexter Yan explains clinical data released by Hutchmed, Jiangsu Hengrui and Innovent Bio at the recent EHA and ADA annual conferences.

[redacted]6[redacted]13[redacted]16[redacted]EHA[redacted]6[redacted]21[redacted]24[redacted]ADA[redacted](Hutchmed)[redacted]syk[redacted]sovleplenib[redacted]ITP[redacted]

[redacted]ADA[redacted]GLP-1[redacted]/GIP [redacted]GLP-1[redacted]/GCG[redacted]GLP-1[redacted]

[redacted]

3[redacted]22[redacted]

Special guest, "Angus" Shipo Xie from Han Kun Law, joins Brian Yang and Dexter Yan to discuss recent trending topics in the China biotech sector. Dexter also talks about the recent clinical data readouts presented at the recent European Hematology Association and American Diabetes Association meetings by Chinese firms *HUTCHMED (China) Limited* on sovleplenib, *Jiangsu Hengrui Medicine Co., Ltd.* on its GLP-1/GIP receptor agonist and *Innovent Biologics, Inc.* on a GLP-1/GCG receptor agonist.

In the second part of the podcast, Angus explains notable changes to China's new rules on Promoting and Regulating Overseas Data Transfers, issued on 22 March by the national

Cybersecurity Administration. What do the new changes mean for drug makers, what are the notable points worth paying close attention and what should companies do to be compliant?

Stories mentioned in this episode:

(Also see "*China Phase III Results Boost Global Prospects For HUTCHMED ITP Drug*" - Scrip, 18 Jun, 2024.)

(Also see "*China Implements Data Transfer Regulation, With Some Waivers*" - Pink Sheet, 3 Apr, 2024.)

Click here to explore this interactive content online